Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ABUS

ABUS - Arbutus Biopharma Corp Stock Price, Fair Value and News

$4.25-0.04 (-0.93%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

83/100

ABUS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

83/100

ABUS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ABUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABUS Price Action

Last 30 days

-1.4%

Last 90 days

-0.2%

Trailing 12 Months

18.7%

ABUS RSI Chart

ABUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABUS Valuation

Market Cap

837.0M

Price/Earnings (Trailing)

5.21

Price/Sales (Trailing)

4.37

EV/EBITDA

-12.33

Price/Free Cashflow

-24.36

ABUS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ABUS Fundamentals

ABUS Revenue

Revenue (TTM)

191.4M

Rev. Growth (Yr)

10.1K%

Rev. Growth (Qtr)

16.9K%

ABUS Earnings

Earnings (TTM)

160.7M

Earnings Growth (Yr)

791.9%

Earnings Growth (Qtr)

4.6K%

ABUS Profitability

EBT Margin

-37.14%

Return on Equity

61.77%

Return on Assets

57.99%

Free Cashflow Yield

-4.1%

ABUS Investor Care

Shares Dilution (1Y)

2.85%

Diluted EPS (TTM)

0.83

ABUS Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2026191.4M000
20256.4M15.4M14.6M14.1M
202413.0M10.1M6.7M6.2M
202333.1M23.5M22.2M18.1M
202221.5M33.4M36.0M39.0M
20217.5M8.4M10.2M11.0M
20206.8M7.7M6.1M6.9M
20195.2M4.6M6.1M6.0M
201811.9M12.1M6.8M5.9M
20173.8M6.1M8.4M10.7M
201619.0M13.2M7.3M1.5M
201515.2M16.8M16.5M24.9M
201411.0M10.0M11.4M15.0M
201312.8M11.4M10.0M8.7M
201216.1M15.5M14.8M14.1M
2011019.1M17.9M16.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Arbutus Biopharma Corp

ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
 CEO
 WEBSITEarbutusbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES96

Arbutus Biopharma Corp Frequently Asked Questions

ABUS is the stock ticker symbol of Arbutus Biopharma Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Arbutus Biopharma Corp is 837.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, ABUS's PE ratio (Price to Earnings) is 5.21 and Price to Sales (PS) ratio is 4.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABUS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Arbutus Biopharma Corp has provided 0.026 (multiply by 100 for percentage) rate of return.